AbbVie’s $100 billion US deal & FDA reforms highlight growing focus on domestic manufacturing, says GlobalData

New Delhi: AbbVie’s $100 billion agreement with the US administration signals a structural recalibration of drug pricing negotiations, tying tariff exemptions and pricing flexibility directly to domestic manufacturing expansion.

Coupled with the evolving US Food and Drug Administration manufacturing reforms, the deal underscores a policy-driven shift that embeds capital investment, supply chain resilience, and advanced biologics capacity into the core of US pharmaceutical strategy,  says GlobalData, a leading intelligence and productivity platform.

Edita Hamzic, Healthcare Analyst at GlobalData, says: “AbbVie’s agreement signals a fundamental shift in US drug pricing policy, where domestic manufacturing investment is no longer a peripheral consideration but a core element of negotiations. Exemptions from import tariffs and future pricing controls provide AbbVie with the flexibility to expand drug manufacturing capacity, modernize production technologies, and strengthen supply chain resilience while continuing to invest in its pipeline.”

Under the three-year deal, AbbVie agreed to lower prices on select Medicaid medicines and expand distribution through the TrumpRx direct-to-patient platform in exchange for exemptions from pharmaceutical import tariffs and future price controls. The company also committed to invest $100 billion over the next decade in US-based research, development, and capital projects, with manufacturing explicitly included.

GlobalData’s Bio/Pharmaceutical Outsourcing Report reveals that the US Food and Drug Administration (FDA) has announced new flexibilities for cell and gene therapy manufacturing, easing certain chemistry, manufacturing, and control (CMC) requirements to better reflect the individualized and small-batch nature of these therapies.

The FDA’s Center for Biologics Evaluation and Research will allow greater discretion for minor manufacturing changes during development and has removed the requirement for three rounds of Process Performance Qualification before commercialization in selected cases to reduce manufacturing bottlenecks without compromising safety, purity, or potency.

At the same time, investment activity continues to reshape global biologics manufacturing capacity. Zydus Lifesciences has completed the acquisition of Agenus’ biologics manufacturing facilities in California and launched a US-based CDMO subsidiary, alongside an exclusive manufacturing agreement for Agenus’ Phase III immuno-oncology candidates.

Meanwhile, Cellares Corp has secured a long-term lease for an automated cell therapy manufacturing facility at Leiden Bio Science Park in the Netherlands, with delivery expected in Q1 2026 and phased occupancy later that year, reinforcing Europe’s role in advanced cell therapy manufacturing.

Hamzic concludes: “As tariff relief, IRA dynamics, and FDA manufacturing flexibilities converge, companies that localize advanced biologics and cell therapy capacity will gain regulatory and pricing leverage. Over time, capital deployment decisions will increasingly be shaped by policy alignment as much as market demand.”